Summit Therapeutics Inc.

SMMT

Held by 2 specialist biotech funds

Share on X

Fund Holdings

Baker Bros. Advisors Rock Springs Capital

AI Signal

**Signal Note: Baker Bros.

AI analyst context — unlock full analysis

Catalysts

PDUFANov 14, 2026ivonescimabNSCLC

Position Details

Baker Bros. AdvisorsNEWFeb 17, 2026

Shares: 36,391,063Value: $636.5M

**Signal Note: Baker Bros. Initiates Major Position in Summit Therapeutics (SMMT)** Baker Bros. Advisors, the largest biotech-specialist fund known for extremely concentrated, high-conviction bets, initiated a new position of ~36.4M shares in Summit Therapeutics, representing a substantial capital deployment ahead of the Nov. 14, 2026 PDUFA date for ivonescimab, a bispecific PD-1/VEGF antibody in non-small cell lung cancer (NSCLC). The size and timing of this initiation suggest strong conviction in the ivonescimab regulatory pathway, likely informed by clinical data readouts positioning the drug as a potential best-in-class competitor to established PD-(L)1 and anti-angiogenic combination regimens. This is a high-signal move given Baker Bros.' track record of deep diligence in onc

Rock Springs CapitalNEW

More SMMT Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

ALKS2 funds ARGX2 funds RCUS2 funds CLDX2 funds NGNE2 funds CNTA2 funds DYN2 funds ELVN

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

**Signal Note: Rock Springs Healthcare Initiates SMMT Position** Rock Springs Capital's $12.4M entry into Summit Therapeutics signals conviction in ivonescimab's NSCLC approval pathway, with a PDUFA decision expected November 2024. The PD-L1/VEGF bispecific represents a competitive play in the crowded first-line NSCLC space, where efficacy versus established combos (e.g., Keytruda + chemo) and durability of response remain key valuation drivers. Near-term catalyst clarity on regulatory outcome and label positioning will likely drive volatility.